palmitoylethanolamide.com.au
HomeResearchYitian 2021

NAAA inhibitor F96 attenuates BBB disruption and secondary injury after traumatic brain injury (TBI)

Yitian Li, Pan Zhou, Ting Hu, Jie Ren, Yaping Xu, Yan Qiu, Canzhong Lu, Yuhang Li. Eur J Pharmacol. 2021 Dec 5:912:174561.

Laboratory studyOther animalsWith F96 (a NAAA inhibitor that raises the body's own palmitoylethanolamide); PEA itself was not given

This study tested palmitoylethanolamide together with F96 (a NAAA inhibitor that raises the body's own palmitoylethanolamide); PEA itself was not given. Its results cannot be assigned to palmitoylethanolamide alone. More combination studies.

Design
Laboratory study
Subjects
Animals with traumatic brain injury; species and numbers not stated in the abstract
Dose used in the study
Not stated in the abstract
Duration
Not stated in the abstract
What was measured
PEA levels in injured cortex; neutrophil infiltration and NAAA; blood-brain barrier disruption; secondary injury and long-term function.

What the authors reported

The study found:

  • Brain injury raised PEA in the injured cortex, which the authors say protects the blood-brain barrier.
  • Infiltrating neutrophils carried NAAA, which degraded PEA and weakened that protection.
  • Inactivating NAAA raised PEA at the injury site, prevented early barrier damage, reduced secondary injury and improved long-term function.

Limits of this study

An animal model; it cannot show effect in people. No palmitoylethanolamide was given; the inhibitor raised the body's own PEA. Species and numbers are not in the abstract. Funding and conflicts not stated in the abstract.

Source

PubMed 34655598 · doi:10.1016/j.ejphar.2021.174561

Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.